Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy

Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy

Background & aims: Despite effective direct-acting antivirals (DAAs), hepatitis C virus (HCV) prevalence is high among people who inject drugs (PWIDs) and non-adherence to therapy remains a major obstacle towards HCV elimination in this subpopulation. To overcome this issue, we have combined...

Full description

Bibliographic Details
Main Authors: M. Schwarz, C. Schwarz, A. Schütz, C. Schwanke, E. Krabb, R. Schubert, S.-T. Liebich, D. Bauer, L. Burghart, L. Brinkmann, E. Gutic, T. Reiberger, H. Haltmayer, M. Gschwantler
Format: Article
Language:English
Published: Elsevier 2023-03-01
Series:Journal of Virus Eradication
Subjects:
PWID
HCV
Opioid
Drug use
Hepatitis
Directly observed therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2055664023000055

Internet

http://www.sciencedirect.com/science/article/pii/S2055664023000055

Similar Items